Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
- PMID: 32380903
- PMCID: PMC7241448
- DOI: 10.1080/22221751.2020.1761267
Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
Abstract
Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9-17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in general as well as vaccine efficacy.
Keywords: COVID-19; SARS; SARS-CoV-2; antibody; cross-neutralization.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous